CH651210A5 - Verfahren zur herstellung einer antikoerper enthaltenden milch zur bekaempfung bakterieller infektionen des magen-darm-traktes. - Google Patents
Verfahren zur herstellung einer antikoerper enthaltenden milch zur bekaempfung bakterieller infektionen des magen-darm-traktes. Download PDFInfo
- Publication number
- CH651210A5 CH651210A5 CH1168/79A CH116879A CH651210A5 CH 651210 A5 CH651210 A5 CH 651210A5 CH 1168/79 A CH1168/79 A CH 1168/79A CH 116879 A CH116879 A CH 116879A CH 651210 A5 CH651210 A5 CH 651210A5
- Authority
- CH
- Switzerland
- Prior art keywords
- milk
- rheumatoid arthritis
- arthritis
- type
- patients
- Prior art date
Links
- 235000013336 milk Nutrition 0.000 title claims description 94
- 239000008267 milk Substances 0.000 title claims description 94
- 210000004080 milk Anatomy 0.000 title claims description 94
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 208000035143 Bacterial infection Diseases 0.000 title claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 title claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 30
- 241000894006 Bacteria Species 0.000 claims description 29
- 241000283690 Bos taurus Species 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 206010003246 arthritis Diseases 0.000 claims description 17
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 10
- 238000004062 sedimentation Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 230000002458 infectious effect Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000012678 infectious agent Substances 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000004520 agglutination Effects 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 2
- 241000588767 Proteus vulgaris Species 0.000 claims description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 2
- 241000607764 Shigella dysenteriae Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 2
- 241000194019 Streptococcus mutans Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 241001312524 Streptococcus viridans Species 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 229940007042 proteus vulgaris Drugs 0.000 claims description 2
- 229940007046 shigella dysenteriae Drugs 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 206010036030 Polyarthritis Diseases 0.000 claims 2
- 206010067868 Skin mass Diseases 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- 206010048998 Acute phase reaction Diseases 0.000 claims 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims 1
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 241000701149 Human adenovirus 1 Species 0.000 claims 1
- 241001135574 Human adenovirus 12 Species 0.000 claims 1
- 241000701122 Human adenovirus 18 Species 0.000 claims 1
- 241001135569 Human adenovirus 5 Species 0.000 claims 1
- 241000193096 Human adenovirus B3 Species 0.000 claims 1
- 241001428586 Human adenovirus D8 Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 241000274177 Juniperus sabina Species 0.000 claims 1
- 208000008771 Lymphadenopathy Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010041660 Splenomegaly Diseases 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000721 bacterilogical effect Effects 0.000 claims 1
- 208000001786 gonorrhea Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010024378 leukocytosis Diseases 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 201000006509 pleuropneumonia Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 210000005222 synovial tissue Anatomy 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 description 29
- 238000002649 immunization Methods 0.000 description 28
- 108060003951 Immunoglobulin Proteins 0.000 description 23
- 102000018358 immunoglobulin Human genes 0.000 description 23
- 239000000902 placebo Substances 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 235000020247 cow milk Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000008476 powdered milk Nutrition 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 3
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 235000010633 broth Nutrition 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229940076085 gold Drugs 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 229940031348 multivalent vaccine Drugs 0.000 description 3
- 229940072689 plaquenil Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003271 Arthritis salmonella Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000421809 Brisaster fragilis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87514078A | 1978-02-06 | 1978-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH651210A5 true CH651210A5 (de) | 1985-09-13 |
Family
ID=25365266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1168/79A CH651210A5 (de) | 1978-02-06 | 1979-02-06 | Verfahren zur herstellung einer antikoerper enthaltenden milch zur bekaempfung bakterieller infektionen des magen-darm-traktes. |
Country Status (10)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE33565E (en) * | 1978-02-06 | 1991-04-02 | Stolle Research And Development Corporation | Prevention and treatment of rheumatioid arthritis |
| US4732757A (en) * | 1978-02-06 | 1988-03-22 | Stolle Research And Development Corporation | Prevention and treatment of rheumatoid arthritis |
| US4490290A (en) * | 1981-02-26 | 1984-12-25 | Internationale Octrooi Maatschappij "Octropa" B.V. | Process for the recovery of immunoglobulins |
| ATE16349T1 (de) * | 1981-04-28 | 1985-11-15 | Stolle Res & Dev | Verfahren zur herstellung einer entzuendungshemmenden rindermilch. |
| JP2561234B2 (ja) * | 1981-05-12 | 1996-12-04 | スト−ル・リサ−チ・アンド・デイベロップメント・コ−ポレ−ション | 抗炎症剤 |
| JPS58154513A (ja) * | 1982-03-09 | 1983-09-14 | Sendai Biseibutsu Kenkyusho | 予防及び治療薬 |
| US4636384A (en) * | 1982-06-03 | 1987-01-13 | Stolle Research & Development Corporation | Method for treating disorders of the vascular and pulmonary systems |
| EP0127712B1 (en) * | 1983-06-07 | 1989-01-11 | The Stolle Research And Development Corporation | Deodorant containing bacterial antibodies |
| JPS6112629A (ja) * | 1984-06-28 | 1986-01-21 | Lion Corp | 口腔内組成物 |
| ATE87215T1 (de) * | 1987-07-21 | 1993-04-15 | Stolle Res & Dev | Verfahren zum erhalten von immunregulierenden faktoren mittels saeugetierimmunisierung. |
| JP2664906B2 (ja) * | 1987-08-13 | 1997-10-22 | ストール・リサーチ・アンド・デイベロップメント・コーポレーション | 改良された哺乳類の免疫法 |
| EP1171161A1 (en) * | 1999-04-19 | 2002-01-16 | Richard Weisbart | Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| CA2423805A1 (en) * | 2000-09-28 | 2002-04-04 | Richard Weisbart | Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin g |
| BR0206869A (pt) * | 2001-01-30 | 2007-01-02 | Lauridsen Group Inc | método para o tratamento de um animal sofrendo de um estado doentio de disfunção imune associado com nìveis alterados de igg ou tnf-delta, composição farmacêutica para o tratamento de distúrbios auto-imunes associados com elevados igg e/ou tnf-delta ou para a potenciação de protocolos de vacina, e método para o tratamento de estado doentio associado com disfunção imune em um animal |
| AU2002309486A1 (en) * | 2001-01-30 | 2002-10-15 | The Lauridsen Group, Incorporated | Methods and compositions for modulating the immune system of animals |
| JP4960632B2 (ja) * | 2006-01-10 | 2012-06-27 | 学校法人北里研究所 | 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 |
| JP5361132B2 (ja) * | 2006-03-10 | 2013-12-04 | 国立大学法人信州大学 | 免疫グロブリンｇを含有する経口用免疫調節剤、その製造方法及び経口用免疫調節剤を配合してなる飲食品 |
| JP2008179572A (ja) * | 2007-01-25 | 2008-08-07 | Shinshu Univ | 免疫グロブリンＦｃフラグメントレセプタータンパク及び／又は免疫グロブリンＦｃフラグメントレセプター様タンパク産生抑制剤及びその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617538C3 (de) * | 1965-10-24 | 1979-10-04 | The Immune Milk Co. Of America, Inc., Cincinnati, Ohio (V.St.A.) | Verfahren zur Herstellung von Tetanus-Antitoxin |
| DE1617769A1 (de) * | 1967-06-10 | 1971-04-01 | Rehm Eberhard | Verfahren zur Gewinnung von spezifischen Antikoerper enthaltender Milch und daraus hergestellter Praeparate |
| JPS5136326A (ja) * | 1974-09-24 | 1976-03-27 | Komatsu Seiren Co | Seikeigorufubooru |
| JPS5837285B2 (ja) * | 1975-05-29 | 1983-08-15 | カブシキガイシヤ ミドリジユウジ | チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ |
| JPS521014A (en) * | 1975-06-17 | 1977-01-06 | Stolle Res & Dev | Pharmaceutically acceptable carrier containing milk immunoglobulin |
| JPS5381613A (en) * | 1976-12-28 | 1978-07-19 | Green Cross Corp:The | Remedies for enteral infection diseases |
| CH627079A5 (en) * | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
-
1979
- 1979-01-30 SE SE7900798A patent/SE448344B/sv not_active IP Right Cessation
- 1979-01-31 NL NL7900766A patent/NL7900766A/xx not_active Application Discontinuation
- 1979-02-02 FR FR7902807A patent/FR2416015A1/fr active Granted
- 1979-02-02 DE DE2904044A patent/DE2904044C2/de not_active Expired
- 1979-02-02 GB GB7903836A patent/GB2013691B/en not_active Expired
- 1979-02-05 JP JP1215279A patent/JPS54113425A/ja active Granted
- 1979-02-05 IT IT47888/79A patent/IT1116524B/it active
- 1979-02-06 DK DK049479A patent/DK158138C/da not_active IP Right Cessation
- 1979-02-06 CH CH1168/79A patent/CH651210A5/de not_active IP Right Cessation
-
1983
- 1983-08-25 HK HK302/83A patent/HK30283A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE7900798L (sv) | 1979-08-07 |
| IT1116524B (it) | 1986-02-10 |
| HK30283A (en) | 1983-09-02 |
| NL7900766A (nl) | 1979-08-08 |
| DK158138C (da) | 1990-08-27 |
| DE2904044A1 (de) | 1979-08-30 |
| DK158138B (da) | 1990-04-02 |
| JPS54113425A (en) | 1979-09-05 |
| DK49479A (da) | 1979-08-07 |
| SE448344B (sv) | 1987-02-16 |
| JPH0160455B2 (enrdf_load_stackoverflow) | 1989-12-22 |
| GB2013691A (en) | 1979-08-15 |
| FR2416015A1 (fr) | 1979-08-31 |
| IT7947888A0 (it) | 1979-02-05 |
| FR2416015B1 (enrdf_load_stackoverflow) | 1983-06-17 |
| DE2904044C2 (de) | 1986-02-06 |
| GB2013691B (en) | 1982-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69722217T2 (de) | Verewndung von hyperimmunisierte milch und/oder ei zur behandlung von magen-darm verletzungen | |
| DE3689717T2 (de) | Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung. | |
| DE2904044C2 (de) | Immungammaglobulin-(IgG)-Präparat, Verfahren zu seiner Herstellung und dessen Verwendung | |
| DE3504221C2 (de) | Mittel zur passiven Immunisierung von Säugern | |
| US4732757A (en) | Prevention and treatment of rheumatoid arthritis | |
| DE4493997C2 (de) | Neue abgeschwächte Pseudomonas-Aeruginosa-Stämme | |
| DE69711661T2 (de) | Micrococcin antibiotika zur prävention und therapie der mastitis | |
| DE69834490T2 (de) | Verfahren zur herstellung von immunoglobulin a in milch | |
| DE2542792A1 (de) | Verfahren zur erhoehung der antikoerpermenge in der milch von milchabsondernden rindern | |
| DE69032207T2 (de) | Einführung von bakterien in ovo | |
| EP0173241B1 (de) | Vakzine zur Behandlung der Harnwegsinfektionen | |
| DE3887686T2 (de) | Bakterielle zubereitung für die prophylaxe und behandlung von entzuendungen und allergischen beschwerden. | |
| DE69128781T2 (de) | Zusammensetzung und methode zur immunstimulierung in säugetieren | |
| WO2012136534A2 (de) | Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten | |
| DE60216906T2 (de) | Anti-pilyrosporum ovale igy und dessen verwendung | |
| DE69021791T2 (de) | Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen. | |
| DE602004005963T2 (de) | Verwendung von vogelantikörpern | |
| DE69028219T2 (de) | Verwendung von honig als impfstoff | |
| DE60010886T2 (de) | Extrakte, formulierung und verwendung von medikamenten aus blättern von cajanus cajan(l.) milsp. | |
| CH661868A5 (de) | Ganzzellen- oder zellwandpraeparate fuer die radio- oder chemotherapie von tumoren. | |
| DE2334376A1 (de) | Immunologisches produkt, seine verwendung und verfahren zu seiner herstellung | |
| DE2854723C3 (de) | Hetero-Impfstoff zur therapeutischen Behandlung des Trichomonas -Syndroms und Verfahren zu seiner Herstellung | |
| DE102011006781A1 (de) | Antikörperprodukt, umfassend n spezifische Antikörper | |
| DE3118148A1 (de) | Antiallergisches praeparat und verfahren zu seiner herstellung | |
| DE2421084A1 (de) | Idfidobakterien enthaltendes praeparat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |